Newsroom
The Latest News From the Ivy Center
The Ivy Brain Tumor Center at Barrow Neurological Institute strives to be a valuable resource for any brain tumor or brain cancer-related media needs. Our media relations team is happy to help answer questions and arrange interviews. The expert neurosurgeons, neuro-oncologists and scientists at the Ivy Center are available to speak on a variety of topics.
Our state-of-the-art media studio is available for audio and video interviews. We can also arrange filming opportunities at various locations around the center and labs.
To contact the media relation team, call 602-406-7437 or email: [email protected].
Please see below for the latest media coverage and news from the Ivy Center. To read about our inspiring patients and those behind the scenes at the Ivy Center, visit the Ivy Blog.
Meghan McCain recognizes Ivy Brain Tumor Center
On May 27, 2020, Meghan McCain used her national platform to recognize Brain Tumor Awareness Month and her personal connection to this deadly disease on The View. She encourages people to support the Ivy Brain Tumor Center in our mission to cure brain cancer.
Ivy Brain Tumor Center Launches New Clinical Trial For Recurrent Glioblastoma
The Ivy Brain Tumor Center at Barrow Neurological Institute announced that patient recruitment has opened for a Phase 0 clinical trial to evaluate two targeted therapy drugs, abemaciclib and LY3214996. The study will evaluate central nervous system (CNS) penetration in patients with recurrent glioblastoma scheduled for resection. This is the first time a combination of these two drugs will be tested in brain tumor patients.
Ivy Foundation Makes Multi-million Dollar Contribution To AZ Coronavirus Relief Fund
“It’s very important to me that the medical personnel in this state have the right tools and supplies to fight this battle,” said Catherine Ivy, co-founder of the Ivy Brain Tumor Center.
Barrow Neurosurgeon to Study Rewiring of Brain in Diabetes
Barrow Neurological Institute neurosurgeon, Dr. Zaman Mirzadeh has received a three-year, $1.8 million grant from the U.S. Department of Defense (DoD) to study the rewiring of the brain to normalize blood sugar levels in diabetes.
As a member of the Ivy Center team, Dr. Mirzadeh runs a lab focused on identifying unique metabolic pathways co-opted by glioblastoma to drive tumor growth.
3 Questions on Phase 0 Clinical Trials for Brain Tumors
The Ivy Brain Tumor Center at the Barrow Neurological Institute is a nonprofit center conducting early phase clinical trials of new therapeutics for brain tumors. In this interview with Oncology Times, Dr. Nader Sanai explains how the phase 0 trials work and why the center is so excited about them.
Ivy Brain Tumor Center Expands Phase 0 Clinical Trials Program to the East Valley
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced a partnership with two East Valley hospitals to expand its novel Phase 0 clinical trials program, the first of its kind in neuro-oncology.
Woman of the Week Podcast: Catherine Ivy
Catherine Ivy, who lost her husband a decade ago to a devastating and sudden brain cancer, shares her personal journey of grief and purpose, which led to the founding of the Ivy Brain Tumor Center at the Barrow Neurological Institute.
Cancer Today Magazine cover story features Lanette Veres of the Gray Matters Foundation
Brain cancer survivor Lanette Veres sends cards and packages to others with the disease. She believes no one should face cancer alone.
Catherine Ivy: A Tireless Advocate for Brain Cancer Patients
In this edition of The Onco’Zine Brief, Peter Hofland talks with Catherine Ivy about how after losing her husband Ben to glioblastoma she became a tireless advocate for brain cancer patients.
First-in-human Study to Determine Effectiveness of Novel, Non-invasive Therapy for Brain Cancer
The Ivy Brain Tumor Center at the Barrow Neurological Institute and SonALASense have signed an strategic agreement to jointly test a new and non-invasive drug-device combination, called sonodynamic therapy or SDT, for the treatment of recurrent glioblastoma.